Switching from Saxenda to Wegovy: what changes, what stays the same

You've been on Saxenda a while. Here's how Wegovy is different.

Picture this: you've been injecting Saxenda daily for several months, the nausea has settled, and you've made progress. Then your doctor mentions semaglutide. It's natural to wonder what you'd actually be changing.

The core difference is the mechanism. Saxenda contains liraglutide, a GLP-1 receptor agonist injected every single day. Wegovy contains semaglutide, also a GLP-1 receptor agonist, but injected just once a week. For many people, dropping from seven injections a week to one is itself a meaningful shift in day-to-day life.

Beyond frequency, the clinical trial results differ. In the STEP 1 trial, semaglutide 2.4mg produced an average weight reduction of around 15% over 68 weeks, as published in the New England Journal of Medicine. Liraglutide's trials showed more modest averages. That gap in evidence is part of why NICE subsequently recommended semaglutide (as Wegovy) for eligible adults, and why some prescribers encourage a switch for patients who have plateaued or are finding daily dosing difficult to sustain. If you want a detailed side-by-side breakdown, our guide to how Saxenda and Wegovy compare across the key measures sets it out clearly.

One practical note for women on oral contraceptives: when starting Wegovy, there's no equivalent advisory about reduced pill absorption that exists for tirzepatide, so that particular concern doesn't carry across from some other GLP-1 switches. Still, any hormonal or other medication interaction is worth raising with your prescriber before you change.

Important to say plainly: nume does not dispense Saxenda. If you're currently on Saxenda and considering a switch, we can discuss Wegovy (and other licensed weight-loss treatments) through our free consultation process.

What the switch process looks like in practice

Switching from Saxenda to Wegovy isn't simply stopping one pen and starting another the next morning. The timing and starting dose of Wegovy after liraglutide needs to be agreed with your prescriber. There's no single universal protocol, individual factors like your current dose, how long you've been on Saxenda, and your tolerance history all shape the plan.

The practical steps of how to switch from Saxenda to Wegovy are worth understanding before you begin. Wegovy starts at 0.25mg weekly and is titrated upward (roughly every four weeks) through 0.5mg, 1.0mg, 1.7mg and then 2.4mg. A higher 7.2mg dose was approved by the MHRA in early 2026 for adults with a BMI of 30 or above, and a dedicated single-dose pen for that strength followed in April 2026. Whether the standard or higher dose pathway is appropriate for you is a prescriber decision, not a self-selection one.

Some people find GI side effects resurface briefly when switching, nausea, loose stools, or low appetite that feels stronger than it did mid-way through Saxenda. This usually reflects the body adjusting to a different molecule rather than a sign something has gone wrong. If symptoms persist or feel severe, that's a reason to contact your prescriber rather than push through alone. You can report any suspected adverse effects through the MHRA's Yellow Card scheme.

If you order before 12pm on a weekday, a clinician reviews your consultation the same day. Many patients tell us that kind of turnaround matters when they're mid-treatment and don't want a gap.

Are you eligible to switch to Wegovy privately?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 and above if there's at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. The fact that you're already established on Saxenda doesn't automatically qualify or disqualify you, the prescriber assesses your current health picture from scratch.

On the NHS, Wegovy sits under NICE guidance TA875, which restricts it to specialist weight management services and caps use at two years. That means many people who are clinically suitable don't access it on the NHS at all, either because of waiting lists or because they fall just outside the specialist-referral pathway.

Private treatment through a registered pharmacy removes the waiting list. It doesn't remove clinical scrutiny. A GPhC-registered prescriber still reviews every consultation before anything is approved. If you want to understand the broader landscape of switching to Wegovy from any previous treatment, that context is worth reading alongside this page. For those arriving from a different injectable, our page on what switching from Ozempic to Wegovy involves illustrates how the transition process works in practice. And if you're also weighing up whether Mounjaro might suit you better, a look at how a Mounjaro-to-Wegovy switch compares gives a sense of what those clinical trade-offs involve.

Which option suits you isn't something a webpage resolves. It's a conversation our prescribers have with you. Speak to our prescribers through the free consultation, and they'll work through your history, your current treatment and your goals together.